Market Access Restrictions To Entresto Are 'Frustrating,' ICER Official Says
This article was originally published in The Pink Sheet Daily
Executive Summary
When pharmacoeconomic analysis points to the cost effectiveness of a new medicine, payers should ease restrictions, ICER Chief Scientific Officer Dan Ollendorf tells ISPOR meeting, pointing to Novartis’ Entresto as a 'frustrating' example.